Concomitant medications and clinical outcomes in idiopathic pulmonary fibrosis

This post hoc exploratory analysis found no clear associations between frequently used concomitant medication combinations and disease progression in 1450 patients with IPF enrolled in phase III trials, but several combinations may require further study. http://bit.ly/2ZzyMXR Patients with idiopathic pulmonary fibrosis (IPF) frequently have a substantial burden of comorbidities [1]. Antifibrotic therapy is recommended to slow the progression of IPF [2]. Patients receiving antifibrotic therapy frequently receive concomitant medications for the management of comorbidities [1, 3–9]. Previous post hoc analyses of antacids, statins, metformin, anticoagulants and angiotensin modulators in patients with IPF enrolled in phase III randomised controlled trials (RCTs) have generated hypotheses on the impact of these treatments on IPF outcomes [3–9]. The effects of multiple concomitant medications in patients with IPF have been largely unexplored. The objective of the present analyses was to explore the association between use of combinations of frequently prescribed concomitant medications and disease outcomes in patients with IPF. eng Ingelheim, Galapagos and Roche, during the conduct of the study. Conflict of interest: D.J. Lederer reports personal fees from Fibrogen, Galapagos, Roche, Global Blood Therapeutics, Sanofi Genzyme and Veracyte, during the conduct of the study. Conflict of interest: V. Cottin reports grants and personal fees from Boehringer Ingelheim and Roche, personal fees from Actelion, Bayer, Celgene, Galapagos, Gilead, GlaxoSmithKline, Merck Sharp and Dohme, Novartis, Promedior and Sanofi, during the conduct of the study. Conflict of interest: N. Kahn reports grants and personal fees from Boehringer Ingelheim and Roche, during the conduct of the study. Conflict of interest: B. Ley reports personal fees from Roche/Genentech, during the conduct of the study. Conflict of interest: C. Vancheri reports grants and personal fees from Boehringer Ingelheim and Roche, and personal fees from Chiesi Farmaceutici, during the conduct of the study. Conflict of interest: D. Weycker is an employee of Policy Analysis Inc. (PAI). Conflict of interest: M. Atwood is an employee of Policy Analysis Inc. (PAI). Conflict of interest: K-U. Kirchgaessler is an employee of F. Hoffmann-La Roche Ltd. Conflict of interest: C.J. Ryerson reports grants and personal fees from Boehringer Ingelheim and Roche, during the conduct of the study.

• Kreuter, M.
• Lederer, D. J.
• Cottin, V.
• Kahn, N.
• Ley, B.
• Vancheri, C.
• Weycker, D.
• Atwood, M.
• Kirchgaessler, K. U.
• Ryerson, C. J.